1.01
price down icon1.08%   -0.011
after-market After Hours: .99 -0.02 -1.98%
loading
Akari Therapeutics Plc Adr stock is traded at $1.01, with a volume of 77,166. It is down -1.08% in the last 24 hours and up +32.89% over the past month. Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
See More
Previous Close:
$1.021
Open:
$0.99
24h Volume:
77,166
Relative Volume:
0.45
Market Cap:
$32.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-2.9015
EPS:
-0.3481
Net Cash Flow:
-
1W Performance:
+32.81%
1M Performance:
+32.89%
6M Performance:
-18.55%
1Y Performance:
-65.76%
1-Day Range:
Value
$0.98
$1.0846
1-Week Range:
Value
$0.76
$1.24
52-Week Range:
Value
$0.5714
$3.70

Akari Therapeutics Plc Adr Stock (AKTX) Company Profile

Name
Name
Akari Therapeutics Plc Adr
Name
Phone
(646) 350-0702
Name
Address
22 BOSTON WHARF ROAD, BOSTON
Name
Employee
12
Name
Twitter
@AkariTX
Name
Next Earnings Date
2024-04-29
Name
Latest SEC Filings
Name
AKTX's Discussions on Twitter

Compare AKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.01 33.30M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-18-25 Initiated Maxim Group Buy
Jan-04-19 Upgrade B. Riley FBR Neutral → Buy
Feb-08-18 Initiated B. Riley FBR, Inc. Neutral
Sep-22-17 Upgrade William Blair Mkt Perform → Outperform
May-31-17 Upgrade Chardan Capital Markets Sell → Neutral
Apr-17-17 Reiterated Chardan Capital Markets Sell
Jul-11-16 Initiated Chardan Capital Markets Sell
View All

Akari Therapeutics Plc Adr Stock (AKTX) Latest News

pulisher
Sep 25, 2025

Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews

Sep 25, 2025
pulisher
Sep 24, 2025

Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa

Sep 24, 2025
pulisher
Sep 24, 2025

Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India

Sep 24, 2025
pulisher
Sep 24, 2025

First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan

Sep 24, 2025
pulisher
Sep 22, 2025

Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com

Sep 22, 2025
pulisher
Sep 19, 2025

Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Institutional scanner results for ANSYS Inc.Entry Point & Verified Technical Trade Signals - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Does SRTY fit your quant trading modelPortfolio Gains Report & Stock Timing and Entry Methods - newser.com

Sep 19, 2025
pulisher
Sep 17, 2025

Akari Therapeutics files patent for novel cancer treatment approach By Investing.com - Investing.com South Africa

Sep 17, 2025
pulisher
Sep 17, 2025

Akari Therapeutics files patent for novel cancer treatment approach - Investing.com

Sep 17, 2025
pulisher
Sep 17, 2025

Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology - Stock Titan

Sep 17, 2025
pulisher
Sep 16, 2025

Is BSIIU stock reversal real or fake2025 Market Overview & Verified Swing Trading Watchlists - newser.com

Sep 16, 2025
pulisher
Sep 14, 2025

Security Solutions Inc.2025 Market Outlook & Smart Money Movement Tracker - newser.com

Sep 14, 2025
pulisher
Sep 14, 2025

Applying big data sentiment scoring on HLITJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com

Sep 14, 2025
pulisher
Sep 05, 2025

Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan

Sep 05, 2025
pulisher
Sep 03, 2025

Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan

Sep 03, 2025
pulisher
Aug 30, 2025

Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser

Aug 30, 2025
pulisher
Aug 29, 2025

What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser

Aug 29, 2025
pulisher
Aug 28, 2025

Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser

Aug 28, 2025
pulisher
Aug 28, 2025

Analyzing recovery setups for Guardian Pharmacy Services Inc. investorsMarket Volume Report & Weekly High Return Stock Forecasts - Newser

Aug 28, 2025
pulisher
Aug 21, 2025

Akari Therapeutics completes $2.8 million note offering and extends warrant terms - Investing.com

Aug 21, 2025
pulisher
Aug 19, 2025

Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan

Aug 19, 2025
pulisher
Aug 14, 2025

Cancer Drug Developer Akari Therapeutics Showcases Pipeline at Webull Biotech Conference - Stock Titan

Aug 14, 2025
pulisher
Aug 09, 2025

Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser

Aug 09, 2025
pulisher
Jul 31, 2025

Insider Stock Buying Reaches US$1.79m On Akari Therapeutics - Sahm

Jul 31, 2025
pulisher
Jul 29, 2025

Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan

Jul 29, 2025
pulisher
Jul 23, 2025

Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan

Jul 23, 2025
pulisher
Jul 22, 2025

Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan

Jul 22, 2025
pulisher
Jul 11, 2025

INKT Stock Quote Price and Forecast - CNN

Jul 11, 2025
pulisher
Jul 01, 2025

Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com

Jul 01, 2025
pulisher
Jun 25, 2025

Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan

Jun 25, 2025
pulisher
Jun 24, 2025

AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan

Jun 24, 2025
pulisher
Jun 18, 2025

Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan

Jun 18, 2025
pulisher
May 29, 2025

Oncology Deal Veteran Mark Kubik Joins Akari Therapeutics to Accelerate ADC Pipeline Growth - Stock Titan

May 29, 2025
pulisher
May 22, 2025

Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan

May 22, 2025
pulisher
May 17, 2025

Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 17, 2025
pulisher
May 01, 2025

Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Akari Therapeutics appoints new head of oncology business - Investing.com

May 01, 2025
pulisher
Apr 22, 2025

Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan

Apr 22, 2025
pulisher
Apr 17, 2025

Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks

Apr 17, 2025
pulisher
Apr 16, 2025

Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan

Apr 16, 2025
pulisher
Mar 20, 2025

Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com

Mar 20, 2025
pulisher
Mar 03, 2025

Akari Therapeutics secures $7.6 million in private placement - Investing.com

Mar 03, 2025
pulisher
Feb 25, 2025

Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas

Feb 25, 2025
pulisher
Feb 19, 2025

Citi reveló que Ecopetrol ha publicado la guía de sus resultados para el cuarto trimestre de 2024 - Yahoo Finanzas

Feb 19, 2025
pulisher
Dec 18, 2024

Akari Therapeutics appoints new CEO and board member - Investing.com

Dec 18, 2024
pulisher
Sep 17, 2024

Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - Stock Titan

Sep 17, 2024
pulisher
Jun 19, 2024

Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas

Jun 19, 2024

Akari Therapeutics Plc Adr Stock (AKTX) Financials Data

There is no financial data for Akari Therapeutics Plc Adr (AKTX). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Cap:     |  Volume (24h):